LON:VAL ValiRx (VAL) Share Price, News & Analysis GBX 0.60 0.00 (0.00%) As of 07/4/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ValiRx Stock (LON:VAL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ValiRx alerts:Sign Up Key Stats Today's Range 0.60▼ 0.6550-Day Range 0.46▼ 0.7552-Week Range 0.38▼ 3.09Volume714,753 shsAverage Volume6.15 million shsMarket Capitalization£2.28 millionP/E RatioN/ADividend Yield0.63%Price TargetN/AConsensus RatingN/A Company Overview ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development. Read More Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VAL Stock News HeadlinesValiRx signs licence with Ambrose worth GBP16 million plus royaltiesJune 20, 2025 | lse.co.ukValiRx subsidiary enters evaluation agreement with Omios BiologicsJune 3, 2025 | lse.co.ukElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 5 at 2:00 AM | Brownstone Research (Ad)ValiRx Expands Cancer Therapeutics Through Strategic PartnershipsApril 30, 2025 | tipranks.comValiRx shares fall as ends collaboration with Imperial College LondonFebruary 25, 2025 | lse.co.ukValiRx PLC Reports Change in Major Shareholder HoldingsJanuary 2, 2025 | tipranks.comValiRx plc Announces Change in Major ShareholdingsDecember 31, 2024 | tipranks.comAIM WINNERS & LOSERS: Strong 2024 for Quadrise and RosebankDecember 31, 2024 | lse.co.ukSee More Headlines VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed this year? ValiRx's stock was trading at GBX 0.65 on January 1st, 2025. Since then, VAL stock has decreased by 7.7% and is now trading at GBX 0.60. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) announced its quarterly earnings results on Friday, June, 6th. The company reported ($1.45) earnings per share (EPS) for the quarter. ValiRx had a negative trailing twelve-month return on equity of 55.84% and a negative net margin of 20,554.01%. How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO). Company Calendar Last Earnings6/06/2025Today7/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPetroleum And Natural Gas Current SymbolLON:VAL CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees5,450Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.71 million Net Margins-20,554.01% Pretax MarginN/A Return on Equity-55.84% Return on Assets-35.98% Debt Debt-to-Equity Ratio0.44 Current Ratio6.65 Quick Ratio1.27 Sales & Book Value Annual Sales£27.78 thousand Price / Sales82.00 Cash FlowGBX 0.01 per share Price / Cash Flow62.50 Book ValueGBX 2.67 per share Price / Book0.22Miscellaneous Outstanding Shares379,605,148Free FloatN/AMarket Cap£2.28 million OptionableNot Optionable Beta0.59 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:VAL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ValiRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
